A A A

 

Wichtige Puklikationen seit 01.01.2007:

 

[Choosing wisely recommendations in hematology and oncology]. Krause SW, Neubauer A.
Internist (Berl). 2017 Jun;58(6):545-549.

 

Immunosuppressive capacity of mesenchymal stem cells correlates with metabolic activity and can be enhanced by valproic acid. Killer MC, Nold P, Henkenius K, Fritz L, Riedlinger T, Barckhausen C, Frech M, Hackstein H, Neubauer A, Brendel C.
Stem Cell Res Ther. 2017 Apr 26;8(1):100.

 

Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with RCSD1-ABL1-positive acute lymphoblastic leukemia. Frech M, Jehn LB, Stabla K, Mielke S, Steffen B, Einsele H, Metzelder SK, Neubauer A.
Haematologica. 2017 Apr;102(4):e160-e162.

 

[Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma]. Neubauer A.
Internist (Berl). 2017 Apr;58(4):409-423.

 

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Schütz C, Inselmann S, Sausslele S, Dietz CT, Mu Ller MC, Eigendorff E, Brendel CA,Metzelder SK, Bru Mmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Xavier Mahon F, Pfirrmann M, Burchert A.
Leukemia. 2017 Apr;31(4):829-836.

 

PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation. Albring JC, Inselmann S, Sauer T, Schliemann C, Altvater B, Kailayangiri S, Rössig C, Hartmann W, Knorrenschild JR, Sohlbach K, Groth C, Lohoff M, Neubauer A, Berdel WE, Burchert A, Stelljes M.
Bone Marrow Transplant. 2017 Feb;52(2):317-320.

 

A Gain-Of-Function Mutation in the Plcg2 Gene Protects Mice from Helicobacter felis-Induced Gastric MALT Lymphoma. Gossmann J, Stolte M, Lohoff M, Yu P, Moll R, Finkernagel F, Garn H, Brendel C, Bittner A, Neubauer A, Huynh MQ.
PLoS One. 2016 Mar 11;11(3):e0150411.

 

Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia. Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage M, Thiem U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppeney R, Herr W, Baldus CD, Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, Hänel M, Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M, Repp R, Link H, Kiani A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U; Study Alliance Leukemia Group.
Leukemia. 2016 Mar;30(3):555-61.

 

Karyotype complexity and prognosis in acute myeloid leukemia. Stölzel F, Mohr B, Kramer M, Oelschlägel U, Bochtler T, Berdel WE, Kaufmann M, Baldus CD, Schäfer-Eckart K, Stuhlmann R, Einsele H, Krause SW, Serve H, Hänel M, Herbst R, Neubauer A, Sohlbach K, Mayer J, Middeke JM, Platzbecker U, Schaich M, Krämer A, Röllig C, Schetelig J, Bornhäuser M, Ehninger G.
Blood Cancer J. 2016 Jan 15;6:e386.

 

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia.
Lancet Oncol. 2015 Dec;16(16):1691-9.

 

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N.
Leukemia. 2015 Oct;29(10):2062-8.

 

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R.
Leukemia. 2015 May;29(5):1123-32.

 

Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation. Brendel C, Teichler S, Millahn A, Stiewe T, Krause M, Stabla K, Ross P, Huynh M, Illmer T, Mernberger M, Barckhausen C, Neubauer A.
PLoS One. 2015 Apr 22;10(4):e0123181.

 

Expression and pro-survival function of phospholipase Cγ2 in diffuse large B-cell lymphoma. Huynh MQ, Goßmann J, Gattenlöehner S, Klapper W, Wacker HH, Ramaswamy A, Bittner A, Kaiser U, Neubauer A.
Leuk Lymphoma. 2015 Apr;56(4):1088-95.

 

Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation. Fouladi F, Jehn LB, Metzelder SK, Hub F, Henkenius K, Burchert A, Brendel C, Stiewe T, Neubauer A.
Leuk Lymphoma. 2015;56(9):2690-8.

 

[Complications after allogeneic bone marrow and stem cell transplantation]. Wollmer E, Neubauer A.
Internist (Berl). 2014 May;55(5):547-60; quiz 561.

 

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saußele S, Hochhaus A.
J Clin Oncol. 2014 Feb 10;32(5):415-23.

 

[Side effects of tumor pharmacotherapy. What internists should know]. Wollmer E, Neubauer A.
Internist (Berl). 2011 Dec;52(12):1429-45; quiz 1446.

 

Gastric mucosa-associated lymphoid tissue lymphoma: how to attack the T… for two? Neubauer A, Huynh M.
Leuk Lymphoma. 2011 Dec;52(12):2203-4.

 

α4 integrin levels on mobilized peripheral blood stem cells predict rapidity of engraftment in patients receiving autologous stem cell transplantation. Hartz B, Volkmann T, Irle S, Loechelt C, Neubauer A, Brendel C.
Blood. 2011 Aug 25;118(8):2362-5.

 

[Chronic myeloid leukemia. Diagnostics, therapy and future strategy]. Burchert A, Neubauer A.
Internist (Berl). 2011 Mar;52(3):283-93; quiz 294-5.

 

[New approaches to lecture medicine--or: what can we learn from television?]. Schaefer JR, Jerrentrup A, Neubauer A.
Dtsch Med Wochenschr. 2010 Dec;135(51-52):2596-600.

 

High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Lorch A, Neubauer A, Hackenthal M, Dieing A, Hartmann JT, Rick O, Bokemeyer C, Beyer J.
Ann Oncol. 2010 Apr;21(4):820-5.

 

Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. Meyer M, Rübsamen D, Slany R, Illmer T, Stabla K, Roth P, Stiewe T, Eilers M, Neubauer A.
PLoS One. 2009 Nov 5;4(11):e7768.

 

["Malignant" ARDS]. Metzelder SK, Reinke C, Walthers EM, Barth P, Vogelmeier C, Neubauer A, Bals R.
Internist (Berl). 2009 Oct;50(10):1272, 1274-7.

 

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, Eilers M, Enghofer E, Neubauer A, Burchert A.
Blood. 2009 Jun 25;113(26):6567-71.

 

Clinical management of massive retroperitoneal hemorrhage after bone marrow biopsy. Neesse A, Kalinowski M, Walthers EM, Görg C, Neubauer A.
Leuk Lymphoma. 2009 Mar;50(3):475-7.

 

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. Neubauer A, Maharry K, Mrózek K, Thiede C, Marcucci G, Paschka P, Mayer RJ, Larson RA, Liu ET, Bloomfield CD.
J Clin Oncol. 2008 Oct 1;26(28):4603-9.

 

[Molecular tumour therapy: antibodies and small molecules]. Wilhelm C, Neubauer A.
Internist (Berl). 2008 May;49(5):581-92.

 

Expression profiling reveals specific gene expression signatures in gastric MALT lymphomas. Huynh MQ, Wacker HH, Wündisch T, Sohlbach K, Kim TD, Krause M, Stabla K, Roth P, Fischbach W, Stolte M, Neubauer A.
Leuk Lymphoma. 2008 May;49(5):974-83.

 

[Sepsis-like disease in an immunocompromised patient with a travel history to Mallorca]. Hagenah GC, Wündisch T, Eckstein E, Zimmermann S, Holst F, Grimm W, Neubauer A, Lohoff M.
Internist (Berl). 2007 Jul;48(7):727-30.

 

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S, Ambudkar SV, Wang Y, Wennemuth G, Burchert A, Boudriot U, Neubauer A.
Leukemia. 2007 Jun;21(6):1267-75.